Briefing
Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial
Phase 3 D-VRd vs VRd in transplant-ineligible or transplant-deferred NDMM. At median follow-up 58.7 months, MRD-negativity rate 60.9% vs 39.4% (OR 2.37, 95% CI 1.58-3.55, P<0.0001); ≥CR 81.2% vs 61.6% (P<0.0001); sustained MRD negativity ≥12 months 48.7% vs 26.3% (P<0.0001). Risk of progression or death was 43% lower with D-VRd (HR 0.57, 95% CI 0.41-0.79, P=0.0005). Level 2. A dedicated MRD analysis is Zweegman et al., Blood Adv 2026 (PMID 42234958).
- Design: paper
- n: 395
- Assay: MRD negativity (and sustained MRD negativity) as a key endpoint